BioScrip, Inc. (NASDAQ:BIOS) has made a 30.13% comeback from a 12-month low price of $1.56. It was seen 4.1% higher, changing the price to $2.03, when the closing bell rang on 5/30/2019. At a recent session, the prices were hovering between $1.95 and $2.03. This company shares are 86.7% off its target price of $3.79 and the current market capitalization stands at $258.85M. The recent change has given its price a 3.7% lead over SMA 50 and -50.97% deficit over its 52-week high. The stock witnessed 5.73% gains, -37.54% declines and -45.14% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found BIOS’s volatility during a week at 4.63% and during a month it has been found around 5.26%.BioScrip, Inc. (BIOS) Top Holders
Institutional investors currently hold around $198 million or 79.6% in BIOS stock. Look at its top three institutional owners: Gilder Gagnon Howe & Co Llc owns $26.54 million in BioScrip, Inc., which represents roughly 10.25% of the company’s market cap and approximately 13.41% of the institutional ownership. Similar statistics are true for the second largest owner, Venor Capital Management Lp, which owns 11,933,605 shares of the stock are valued at $23.27 million. The third largest holder is Blackrock Inc., which currently holds $17.46 million worth of this stock and that ownership represents nearly 6.75% of its market capitalization.
At the end of March reporting period, 60 institutional holders increased their position in BioScrip, Inc. (NASDAQ:BIOS) by some 8,770,220 shares, 67 decreased positions by 13,943,118 and 21 held positions by 78,970,313. That puts total institutional holdings at 101,683,651 shares, according to SEC filings. The stock grabbed 19 new institutional investments totaling 1,784,820 shares while 31 institutional investors sold out their entire positions totaling 5,187,241 shares.BioScrip, Inc. (NASDAQ:BIOS) Insider Trades
Multiple company employees have indulged in significant insider trading. BioScrip, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that CFO Deitsch Stephen has acquired 10,000 shares of BioScrip, Inc. (BIOS) in the trading session dated Nov. 09, 2017. These shares are worth $20,300 and were traded at $2.03 each. The SEC filing shows that GREENLEAF DANIEL E performed a purchase of 15,000 shares. The CEO added these shares by way of transaction on Nov. 09, 2017. The company’s shares were assimilated at $2.03 per share worth to an investment of some $30,450 to the account of GREENLEAF DANIEL E.
Director, Bronfein Michael G, sold 27,000 common shares of BioScrip, Inc. (BIOS) in the open market. In a transaction dated Sep. 15, 2017, the shares were put up for sale at an average price of $2.69, raking in a sum of $72,630. After this sale, 129,669 common shares of BIOS are directly owned by the insider, with total stake valued at $263,228.
In the transaction dated Sep. 07, 2017, a great number of shares sold came courtesy the Director, 10% Owner; Coliseum Capital Management, L disposed a total of 2,846,941 shares at an average price of $2.93, amounting to approximately $8,341,537. The insider now directly owns 1,888,991 shares worth $3,834,652.
Several analysts have released their opinion on BioScrip, Inc. (NASDAQ:BIOS), with 2 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 4 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.86 average brokerage recommendation [T1].